Sept.16 (EIRNS)—Global Times reported yesterday that the Chinese Covid-19 vaccine currently in Phase 3 trial in U.A.E. was approved by U.A.E. on Sep. 14 for urgent use. The U.A.E. has had over 80,000 cases of Covid-19.
The vaccine is an inactivated type developed by the China National Pharmaceutical Group (Sinopharm). Phase 3 clinical trials on the vaccine started in the U.A.E. on July 16. So far it has been given to 31,000 volunteers in the U.A.E., representing 125 nationalities. Mild and expected side effects have occurred, but no severe side effects have been encountered. The volunteers include 1,000 participants who are suffering from chronic diseases, and they suffered no complications after vaccination. Clinical trials on the vaccine are also being conducted in Bahrain, Jordan and Egypt.
The company G42, which is an Abu Dhabi-based artificial intelligence and cloud computing company, is partnering with Sinopharm in this project, under the supervision of the Department of Health of Abu Dhabi. G42 can use AI and supercomputing expertise to process the trial results far more quickly than vaccine trials in the past, G42 CEO Ashish Koshy told {Global Times].
The Jerusalem Post of Sept. 14, in a related article entitled “U.A.E. Approves Vaccine by G42 and China’s Sinopharm,” wrote: “On July 5, the same G42 signed a Memorandum of Understanding with Israel’s leading defense companies Rafael Advanced Defense Systems and Israel Aerospace Industries to work together against Covid-19.” The article also references Gulf News and Khaleej Times as reporting that G42 is the first U.A.E. company to announce it is opening an office in Israel. G42 also has a partnership with the Israeli company Nanoscent to develop technology to help detect suspected cases of Covid-19.
